Kumthorn Malathum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kumthorn Malathum has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Sasisopin Kiertiburanakul
Mahidol University
2 shared publications A. Riewpaiboon
Faculty of Pharmacy,Mahidol University,447 Sri-Ayuthaya Road, Rajathevi,Bangkok 10400,Thailand
1 shared publicationAkeatit Trirattanapikul
1 shared publication- Alison Margaret Hutchinson
Deakin University
1 shared publication - Andrea Driscoll
School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia; School of Nursing and Midwifery, Deakin University, Geelong, Vic, Australia; Department of Cardiology, Austin Health, Melbourne, Vic, Australia
1 shared publication Angsana Phuphuakrat
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 18 May 2024
- Published by Elsevier in Clinical Infection in Practice
- Vol. 23
A rare manifestation: Neisseria meningitidis infection of thyroglossal duct cyst
- 18 May 2024
- Published by Elsevier in Clinical Infection in Practice
- Vol. 23
Open AccessA rare manifestation: Neisseria meningitidis infection of thyroglossal duct cyst
- Open Access
- 11 December 2023
- Published by Springer Nature in Research Square
Impact of removing ESBL testing report from cultures on the selection of antibiotics for the treatment and 30-day mortality of patients infected with ESBL-producing organisms
Background The increasing incidence of carbapenem-resistant organisms is well recognized as a global crisis. Several studies have identified previous carbapenem use as a risk factor for the subsequent development of infections with carbapenem-resistant Gram-negative organisms. We characterized the impact of the removal of the ESBL designation from microbiology reports on inpatient antibiotic prescribing and mortality. Methods This was a historical control and interventional analysis performed in a 1300-bed university hospital to compare 1 year before (1 August 2019 to 31 July 2020) and 1 year after removal of the ESBL designation (1 August 2020 to 31 July 2021), with a 1-month washout period (1 August 2020 to 31 August 2020). All statistical tests were two-tailed, and P < 0.05 was considered statistically significant. Results A total of 213 and 207 patients were included before and after elimination of the ESBL designation in the Hospital Information System. The most commonly isolated organism was Escherichia coli. The most common specimen in which these organisms were detected was urine (57.8% and 62.2%, before and after periods). Definitive prescribing of carbapenems, as the primary outcome, decreased from 56.5–41.3% (P = 0.01); cefepime prescribing decreased from 13.6–3.5% (P < 0.05); and piperacillin-tazobactam use increased significantly from 10.4–28.7% (P < 0.05). TMP-SMX was prescribed more frequently, increasing from 0 to 2.8%; however, this change was not statistically significant. The 30-day mortality rate from any cause did not differ between the before and after periods, with 22/154 patients (14.3%) before and 24/143 (16.8%) after (P = 0.55). There was a non-statistically significant decrease in carbapenem prescriptions for definitive treatment of bacteremia caused by ESBL-producing organisms (84.4% and 68.6%; P = 0.155), while definitive piperacillin-tazobactam prescribing increased from 0 to 6.0% (P = 0.025), comparing the before and after periods, respectively. Carbapenem prescriptions for urinary tract infections decreased from 49.4–28.1% (P = 0.005), while piperacillin-tazobactam was prescribed more often (11.2% versus 32.6%; P = 0.001) (before and after, respectively); carbapenem use for pneumonia did not decrease. Conclusions Definitive prescribing of carbapenems and cefepime decreased and piperacillin-tazobactam use increased after removal of the ESBL report. Our findings confirm the importance of collaboration between microbiology and antimicrobial stewardship programs.
- 11 December 2023
- Published by Springer Nature in Research Square
Open AccessImpact of removing ESBL testing report from cultures on the selection of antibiotics for the treatment and 30-day mortality of patients infected with ESBL-producing organisms
Background The increasing incidence of carbapenem-resistant organisms is well recognized as a global crisis. Several studies have identified previous carbapenem use as a risk factor for the subsequent development of infections with carbapenem-resistant Gram-negative organisms. We characterized the impact of the removal of the ESBL designation from microbiology reports on inpatient antibiotic prescribing and mortality. Methods This was a historical control and interventional analysis performed in a 1300-bed university hospital to compare 1 year before (1 August 2019 to 31 July 2020) and 1 year after removal of the ESBL designation (1 August 2020 to 31 July 2021), with a 1-month washout period (1 August 2020 to 31 August 2020). All statistical tests were two-tailed, and P < 0.05 was considered statistically significant. Results A total of 213 and 207 patients were included before and after elimination of the ESBL designation in the Hospital Information System. The most commonly isolated organism was Escherichia coli. The most common specimen in which these organisms were detected was urine (57.8% and 62.2%, before and after periods). Definitive prescribing of carbapenems, as the primary outcome, decreased from 56.5–41.3% (P = 0.01); cefepime prescribing decreased from 13.6–3.5% (P < 0.05); and piperacillin-tazobactam use increased significantly from 10.4–28.7% (P < 0.05). TMP-SMX was prescribed more frequently, increasing from 0 to 2.8%; however, this change was not statistically significant. The 30-day mortality rate from any cause did not differ between the before and after periods, with 22/154 patients (14.3%) before and 24/143 (16.8%) after (P = 0.55). There was a non-statistically significant decrease in carbapenem prescriptions for definitive treatment of bacteremia caused by ESBL-producing organisms (84.4% and 68.6%; P = 0.155), while definitive piperacillin-tazobactam prescribing increased from 0 to 6.0% (P = 0.025), comparing the before and after periods, respectively. Carbapenem prescriptions for urinary tract infections decreased from 49.4–28.1% (P = 0.005), while piperacillin-tazobactam was prescribed more often (11.2% versus 32.6%; P = 0.001) (before and after, respectively); carbapenem use for pneumonia did not decrease. Conclusions Definitive prescribing of carbapenems and cefepime decreased and piperacillin-tazobactam use increased after removal of the ESBL report. Our findings confirm the importance of collaboration between microbiology and antimicrobial stewardship programs.
- Open Access
Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 28 peritoneal dialyzed (PD) patients, and 14 healthy controls. Participants received two doses of inactivated SARS-CoV-2 vaccine followed by a dose of ChAdOx1 nCoV-19 vaccine. At 6 months, median anti-RBD IgG titers (IQR) significantly declined from baseline in the HD (1741 (1136–3083) BAU/mL vs. 373 (188–607) BAU/mL) and PD (1093 (617–1911) BAU/mL vs. 180 (126–320) BAU/mL) groups, as did the mean percent inhibition of neutralizing antibodies (HD: 96% vs. 81%; PD: 95% vs. 73%) (all p < 0.01). Age and post-vaccination serological response intensity were predictors of early humoral seroprotection loss. In contrast, cell-mediated immunity remained unchanged. In conclusion, humoral immunity declined substantially in dialysis patients, while cell-mediated immunity remained stable 6 months after the extended heterologous primary series of two inactivated SARS-CoV-2/ChAdOx1 nCoV-19 vaccine. A booster dose could be considered in dialysis patients 3 months after this unique regimen, particularly in the elderly or those with a modest initial humoral response.
Open AccessDurability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 28 peritoneal dialyzed (PD) patients, and 14 healthy controls. Participants received two doses of inactivated SARS-CoV-2 vaccine followed by a dose of ChAdOx1 nCoV-19 vaccine. At 6 months, median anti-RBD IgG titers (IQR) significantly declined from baseline in the HD (1741 (1136–3083) BAU/mL vs. 373 (188–607) BAU/mL) and PD (1093 (617–1911) BAU/mL vs. 180 (126–320) BAU/mL) groups, as did the mean percent inhibition of neutralizing antibodies (HD: 96% vs. 81%; PD: 95% vs. 73%) (all p < 0.01). Age and post-vaccination serological response intensity were predictors of early humoral seroprotection loss. In contrast, cell-mediated immunity remained unchanged. In conclusion, humoral immunity declined substantially in dialysis patients, while cell-mediated immunity remained stable 6 months after the extended heterologous primary series of two inactivated SARS-CoV-2/ChAdOx1 nCoV-19 vaccine. A booster dose could be considered in dialysis patients 3 months after this unique regimen, particularly in the elderly or those with a modest initial humoral response.
- Open Access
- 27 June 2019
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 8 (1) , 1-8
Rapid screening and early precautions for carbapenem-resistant Acinetobacter baumannii carriers decreased nosocomial transmission in hospital settings: a quasi-experimental study
Active surveillance has the potential to prevent nosocomial transmission of carbapenem-resistant Acinetobacter baumannii (CRAB). We assessed whether rapid diagnosis using clinical specimen-direct loop-mediated isothermal amplification (LAMP), a rapid molecular diagnostic assay, and subsequent intervention, could reduce CRAB nosocomial transmission in intensive care units (ICUs). A before and after (quasi-experimental) study was conducted in two ICUs at the Mahidol University Faculty of Medicine Ramathibodi Hospital with 3 months of observational period followed by 9 months of interventional period. All patients were screened for CRAB using both the culture and LAMP method from rectal swab and/or bronchial aspirates (intubated patients only) upon admission, weekly thereafter, and upon discharge. During the pre-intervention period, we performed contact precautions based on culture results. In contrast, during the intervention period, we initiated contact precautions within a few hours after sample collection on the basis of LAMP results. A total of 1335 patients were admitted to the ICUs, of which 866 patients (pre-intervention period: 187; intervention period: 679) were eligible for this study. Incidence rate of CRAB infection decreased to 20.9 per 1000 patient-days in the intervention period from 35.2 in the pre-intervention period (P < 0.02). The calculated hazard ratio of CRAB transmission was 0.65 (95% confidence interval [CI], 0.44–0.97). Risk factors for CRAB acquisition included exposure to carbapenem (hazard ratio, 2.54 [95% CI: 1.61–5.57]). LAMP screening for CRAB upon ICU admission proved feasible for routine clinical practice. Rapid screening using LAMP followed by early intervention may reduce CRAB transmission rates in ICUs when compared to conventional intervention.
- 27 June 2019
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 8 (1) , 1-8
Open AccessRapid screening and early precautions for carbapenem-resistant Acinetobacter baumannii carriers decreased nosocomial transmission in hospital settings: a quasi-experimental study
Active surveillance has the potential to prevent nosocomial transmission of carbapenem-resistant Acinetobacter baumannii (CRAB). We assessed whether rapid diagnosis using clinical specimen-direct loop-mediated isothermal amplification (LAMP), a rapid molecular diagnostic assay, and subsequent intervention, could reduce CRAB nosocomial transmission in intensive care units (ICUs). A before and after (quasi-experimental) study was conducted in two ICUs at the Mahidol University Faculty of Medicine Ramathibodi Hospital with 3 months of observational period followed by 9 months of interventional period. All patients were screened for CRAB using both the culture and LAMP method from rectal swab and/or bronchial aspirates (intubated patients only) upon admission, weekly thereafter, and upon discharge. During the pre-intervention period, we performed contact precautions based on culture results. In contrast, during the intervention period, we initiated contact precautions within a few hours after sample collection on the basis of LAMP results. A total of 1335 patients were admitted to the ICUs, of which 866 patients (pre-intervention period: 187; intervention period: 679) were eligible for this study. Incidence rate of CRAB infection decreased to 20.9 per 1000 patient-days in the intervention period from 35.2 in the pre-intervention period (P < 0.02). The calculated hazard ratio of CRAB transmission was 0.65 (95% confidence interval [CI], 0.44–0.97). Risk factors for CRAB acquisition included exposure to carbapenem (hazard ratio, 2.54 [95% CI: 1.61–5.57]). LAMP screening for CRAB upon ICU admission proved feasible for routine clinical practice. Rapid screening using LAMP followed by early intervention may reduce CRAB transmission rates in ICUs when compared to conventional intervention.
- Open Access
- 8 March 2019
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 147, e133
Annual relative increased in inpatient mortality from antimicrobial resistant nosocomial infections in Thailand
Antimicrobial resistance is a major health threat worldwide as it brings about poorer treatment outcome and places economic burden to the society. This study aims to estimate the annual relative increased in inpatient mortality from antimicrobial resistant (AMR) nosocomial infections (NI) in Thailand. A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, Thailand, over 2008–2012. Survival model was used to estimate the hazard ratio of mortality of AMR relative to those patients without resistance (non-AMR) after controlling for nine potential confounders. The majority of NI (73.80%) were caused by AMR bacteria over the study period. Patients in the AMR and non-AMR groups had similar baseline clinical characteristics. Relative to patients in the non-AMR group, the expected hazard ratios of mortality for patients in the AMR group with Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus were 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58), respectively. In the complete absence of AMR bacteria, this study estimated that annually, in Thailand, there would be 111 295 fewer AMR cases and 48 258 fewer deaths.
- 8 March 2019
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 147, e133
Open AccessAnnual relative increased in inpatient mortality from antimicrobial resistant nosocomial infections in Thailand
Antimicrobial resistance is a major health threat worldwide as it brings about poorer treatment outcome and places economic burden to the society. This study aims to estimate the annual relative increased in inpatient mortality from antimicrobial resistant (AMR) nosocomial infections (NI) in Thailand. A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, Thailand, over 2008–2012. Survival model was used to estimate the hazard ratio of mortality of AMR relative to those patients without resistance (non-AMR) after controlling for nine potential confounders. The majority of NI (73.80%) were caused by AMR bacteria over the study period. Patients in the AMR and non-AMR groups had similar baseline clinical characteristics. Relative to patients in the non-AMR group, the expected hazard ratios of mortality for patients in the AMR group with Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus were 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58), respectively. In the complete absence of AMR bacteria, this study estimated that annually, in Thailand, there would be 111 295 fewer AMR cases and 48 258 fewer deaths.
- 1 December 2018
- Published by Elsevier in Infection, Disease & Health
- Vol. 23 (4) , 203-210
A survey of reported behaviours, attitudes and knowledge related to antibiotic use of hospitalised patients in Thailand
- 1 December 2018
- Published by Elsevier in Infection, Disease & Health
- Vol. 23 (4) , 203-210
A survey of reported behaviours, attitudes and knowledge related to antibiotic use of hospitalised patients in Thailand
- Open Access
- 1 February 2016
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 49 (1) , 150-153
Selective IgM deficiency in an adult presenting with Streptococcus pneumoniae septic arthritis
- 1 February 2016
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 49 (1) , 150-153
Open AccessSelective IgM deficiency in an adult presenting with Streptococcus pneumoniae septic arthritis
- 17 September 2010
- Published by Elsevier in Journal of Hospital Infection
- Vol. 76 (4) , 369-371
Epidemiology and risk factors of catheter-associated bloodstream infections among intensive care unit patients: an experience from a tertiary care hospital in Thailand
- 17 September 2010
- Published by Elsevier in Journal of Hospital Infection
- Vol. 76 (4) , 369-371
Epidemiology and risk factors of catheter-associated bloodstream infections among intensive care unit patients: an experience from a tertiary care hospital in Thailand
- Open Access
- 1 January 2007
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 4 (1) , 26
Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings. Lipodystrophy is common and options for switching ART regimen are limited; this situation can lead to patients' poor adherence and antiretroviral resistance. Treatment interruption (TI) in patients with high CD4 cell counts, lipodystrophy, and limited options may be an alternative in resource-limited settings. This study aimed to determine time to resume ART after TI and predictors for early resumption of ART in a resource-limited setting.
- 1 January 2007
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 4 (1) , 26
Open AccessRapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings. Lipodystrophy is common and options for switching ART regimen are limited; this situation can lead to patients' poor adherence and antiretroviral resistance. Treatment interruption (TI) in patients with high CD4 cell counts, lipodystrophy, and limited options may be an alternative in resource-limited settings. This study aimed to determine time to resume ART after TI and predictors for early resumption of ART in a resource-limited setting.